Literature DB >> 7895527

Leukemia-associated changes identified by quantitative flow cytometry: I. CD10 expression.

T Lavabre-Bertrand1, G Janossy, K Ivory, R Peters, L Secker-Walker, A Porwit-MacDonald.   

Abstract

We have compared CD10 antigen expression in normal fetal bone marrow with that of B-linage acute lymphoblastic leukemia (ALL). Both quantitative indirect immunofluoresence (QIFI) and direct immunofluorescence (IF) tests with Quantum beads were used to convert median fluorescence intensity (MFI) values into numbers of antigen molecules expressed per cell (AgE). Lymphoid precursors in the fetal marrow and liver expressed 3-12.5 x 10(3) CD10 molecules/cell with an upper limit of 5 x 10(4)/cell (MaxAgE). The median CD10 AgE in the different cases of acute B-lineage ALL were variable and ranged from undetectable to very high values (> 1.8 x 10(5). In 24 of the 72 cases (33%) tested with QIFI the median CD10 AgE was above the highest values seen in normal samples (> 5 x 10(4)/cell). An additional 23.6% of cases had higher median values than the normal median CD10 AgE. Next, CD10 antigen was quantitated in 78 cases during the routine multiparameter analysis of B-lineage leukemia using CD10/class II/CD34 3-color IF test or CD10/TdT 2-color IF test. The aberrant overexpression was confirmed in 43.6% of ALL cases. The CD10bright display suggested ALL diagnosis even when few cells were available for study, e.g., in early relapse and in ALL masquerading as aplastic anemia. The levels of CD10 expression were maintained in relapse. In addition, different CD10 levels were associated with the various chromosomal alterations: high CD10 levels (> 3 x 10(4)/cell) with hyperdiploidy, low CD10 levels (1.8-4 x 10(3)/cell) with the t(1;19) and undetectable levels (< 1.2 x 10(3)/cell) with the t(4;11) translocations.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7895527     DOI: 10.1002/cyto.990180404

Source DB:  PubMed          Journal:  Cytometry        ISSN: 0196-4763


  9 in total

1.  Levels of expression of CD19 and CD20 in chronic B cell leukaemias.

Authors:  L Ginaldi; M De Martinis; E Matutes; N Farahat; R Morilla; D Catovsky
Journal:  J Clin Pathol       Date:  1998-05       Impact factor: 3.411

Review 2.  Eviction from the sanctuary: Development of targeted therapy against cell adhesion molecules in acute lymphoblastic leukemia.

Authors:  Sonali P Barwe; Anthony Quagliano; Anilkumar Gopalakrishnapillai
Journal:  Semin Oncol       Date:  2017-07-11       Impact factor: 4.929

3.  What you need to know when you go with the flow: pitfalls in the use of flow cytometry.

Authors:  M Pallis; R A Robins
Journal:  Ann Rheum Dis       Date:  1995-10       Impact factor: 19.103

Review 4.  Detection of minimal residual disease (MRD) after bone marrow transplantation (BMT) by multi-parameter flow cytometry (MPFC).

Authors:  A Nagler; R Condiotti; R Rabinowitz; M Schlesinger; M Nguyen; L W Terstappen
Journal:  Med Oncol       Date:  1999-09       Impact factor: 3.064

5.  Differential expression of T cell antigens in normal peripheral blood lymphocytes: a quantitative analysis by flow cytometry.

Authors:  L Ginaldi; N Farahat; E Matutes; M De Martinis; R Morilla; D Catovsky
Journal:  J Clin Pathol       Date:  1996-07       Impact factor: 3.411

6.  Correlation between immunophenotypic diversity and clinical features in B-cell lymphoblastic lymphoma.

Authors:  K Shibata; Y Shimamoto; H Yamada; M Miyahara; N Fukushima; H Yano
Journal:  Ann Hematol       Date:  1995-12       Impact factor: 3.673

Review 7.  Contribution of immunophenotypic and genotypic analyses to the diagnosis of acute leukemia.

Authors:  R Stasi; C G Taylor; A Venditti; G Del Poeta; G Aronica; C Bastianelli; M D Simone; F Buccisano; M C Cox; A Bruno
Journal:  Ann Hematol       Date:  1995-07       Impact factor: 3.673

8.  Quantitative diagnostic imaging of cancer tissues by using phosphor-integrated dots with ultra-high brightness.

Authors:  Kohsuke Gonda; Mika Watanabe; Hiroshi Tada; Minoru Miyashita; Yayoi Takahashi-Aoyama; Takashi Kamei; Takanori Ishida; Shin Usami; Hisashi Hirakawa; Yoichiro Kakugawa; Yohei Hamanaka; Ryuichi Yoshida; Akihiko Furuta; Hisatake Okada; Hideki Goda; Hiroshi Negishi; Kensaku Takanashi; Masaru Takahashi; Yuichi Ozaki; Yuka Yoshihara; Yasushi Nakano; Noriaki Ohuchi
Journal:  Sci Rep       Date:  2017-08-08       Impact factor: 4.379

9.  Prototyping Trastuzumab Docetaxel Immunoliposomes with a New FCM-Based Method to Quantify Optimal Antibody Density on Nanoparticles.

Authors:  A Rodallec; C Franco; S Robert; G Sicard; S Giacometti; B Lacarelle; F Bouquet; A Savina; R Lacroix; F Dignat-George; J Ciccolini; P Poncelet; R Fanciullino
Journal:  Sci Rep       Date:  2020-03-05       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.